全文获取类型
收费全文 | 15681篇 |
免费 | 1179篇 |
国内免费 | 98篇 |
专业分类
耳鼻咽喉 | 249篇 |
儿科学 | 429篇 |
妇产科学 | 161篇 |
基础医学 | 1872篇 |
口腔科学 | 202篇 |
临床医学 | 1956篇 |
内科学 | 3384篇 |
皮肤病学 | 205篇 |
神经病学 | 1440篇 |
特种医学 | 592篇 |
外国民族医学 | 7篇 |
外科学 | 2788篇 |
综合类 | 248篇 |
一般理论 | 9篇 |
预防医学 | 1448篇 |
眼科学 | 227篇 |
药学 | 887篇 |
1篇 | |
中国医学 | 21篇 |
肿瘤学 | 832篇 |
出版年
2023年 | 76篇 |
2022年 | 114篇 |
2021年 | 329篇 |
2020年 | 178篇 |
2019年 | 298篇 |
2018年 | 351篇 |
2017年 | 289篇 |
2016年 | 282篇 |
2015年 | 352篇 |
2014年 | 517篇 |
2013年 | 742篇 |
2012年 | 1023篇 |
2011年 | 1106篇 |
2010年 | 617篇 |
2009年 | 563篇 |
2008年 | 988篇 |
2007年 | 1134篇 |
2006年 | 1032篇 |
2005年 | 995篇 |
2004年 | 890篇 |
2003年 | 822篇 |
2002年 | 789篇 |
2001年 | 226篇 |
2000年 | 181篇 |
1999年 | 188篇 |
1998年 | 190篇 |
1997年 | 166篇 |
1996年 | 133篇 |
1995年 | 134篇 |
1994年 | 115篇 |
1993年 | 123篇 |
1992年 | 135篇 |
1991年 | 129篇 |
1990年 | 166篇 |
1989年 | 126篇 |
1988年 | 105篇 |
1987年 | 128篇 |
1986年 | 111篇 |
1985年 | 110篇 |
1984年 | 69篇 |
1983年 | 71篇 |
1982年 | 41篇 |
1981年 | 52篇 |
1980年 | 46篇 |
1979年 | 70篇 |
1978年 | 49篇 |
1977年 | 42篇 |
1976年 | 38篇 |
1974年 | 43篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Shylaja Srinivasan Ling Chen Jennifer Todd Jasmin Divers Samuel Gidding Steven Chernausek Rose A. Gubitosi-Klug Megan M. Kelsey Rachana Shah Mary Helen Black Lynne E. Wagenknecht Alisa Manning Jason Flannick Giuseppina Imperatore Josep M. Mercader Dana Dabelea Jose C. Florez 《Diabetes》2021,70(4):996
The prevalence of type 2 diabetes in youth has increased substantially, yet the genetic underpinnings remain largely unexplored. To identify genetic variants predisposing to youth-onset type 2 diabetes, we formed ProDiGY, a multiethnic collaboration of three studies (TODAY, SEARCH, and T2D-GENES) with 3,006 youth case subjects with type 2 diabetes (mean age 15.1 ± 2.9 years) and 6,061 diabetes-free adult control subjects (mean age 54.2 ± 12.4 years). After stratifying by principal component–clustered ethnicity, we performed association analyses on ∼10 million imputed variants using a generalized linear mixed model incorporating a genetic relationship matrix to account for population structure and adjusting for sex. We identified seven genome-wide significant loci, including the novel locus rs10992863 in PHF2 (P = 3.2 × 10−8; odds ratio [OR] = 1.23). Known loci identified in our analysis include rs7903146 in TCF7L2 (P = 8.0 × 10−20; OR 1.58), rs72982988 near MC4R (P = 4.4 × 10−14; OR 1.53), rs200893788 in CDC123 (P = 1.1 × 10−12; OR 1.32), rs2237892 in KCNQ1 (P = 4.8 × 10−11; OR 1.59), rs937589119 in IGF2BP2 (P = 3.1 × 10−9; OR 1.34), and rs113748381 in SLC16A11 (P = 4.1 × 10−8; OR 1.04). Secondary analysis with 856 diabetes-free youth control subjects uncovered an additional locus in CPEB2 (P = 3.2 × 10−8; OR 2.1) and consistent direction of effect for diabetes risk. In conclusion, we identified both known and novel loci in the first genome-wide association study of youth-onset type 2 diabetes. 相似文献
102.
Andrea Lin Jasmine A. Mack Brittany Bruggeman Laura M. Jacobsen Amanda L. Posgai Clive H. Wasserfall Todd M. Brusko Mark A. Atkinson Stephen E. Gitelman Peter A. Gottlieb Matthew J. Gurka Clayton E. Mathews Desmond A. Schatz Michael J. Haller 《Diabetes》2021,70(5):1123
Previously, we demonstrated low-dose antithymocyte globulin (ATG) and granulocyte colony-stimulating factor (GCSF) immunotherapy preserved C-peptide for 2 years in a pilot study of patients with established type 1 diabetes (n = 25). Here, we evaluated the long-term outcomes of ATG/GCSF in study participants with 5 years of available follow-up data (n = 15). The primary end point was area under the curve (AUC) C-peptide during a 2-h mixed-meal tolerance test. After 5 years, there were no statistically significant differences in AUC C-peptide when comparing those who received ATG/GCSF versus placebo (P = 0.41). A modeling framework based on mean trajectories in C-peptide AUC over 5 years, accounting for differing trends between groups, was applied to recategorize responders (n = 9) and nonresponders (n = 7). ATG/GCSF reponders demonstrated nearly unchanged HbA1c over 5 years (mean [95% CI] adjusted change 0.29% [–0.69%, 1.27%]), but the study was not powered for comparisons against nonresponders 1.75% (–0.57%, 4.06%) or placebo recipients 1.44% (0.21%, 2.66%). These data underscore the importance of long-term follow-up in previous and ongoing phase 2 trials of low-dose ATG in recent-onset type 1 diabetes. 相似文献
103.
104.
Ann Taber Youngrok Park Alana Lelo Frederik Prip Jerry Xiao Deborah L. Berry Krysta Chaldekas Jørgen Bjerggaard Jensen George Philips Jung-Sik Kim Brent T. Harris Lars Dyrskjøt Todd Waldman 《Urologic oncology》2021,39(7):438.e1-438.e9
ObjectiveImprovements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.Materials and MethodsSTAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.ResultsSTAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.ConclusionsSTAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted. 相似文献
105.
106.
107.
108.
109.
Ashley Lacombe-Duncan PhD MSW Hannah Kia PhD MSW Carmen H. Logie PhD MSW Kieran P. Todd BA Yasmeen Persad Gabrielle Leblanc Kelendria Nation Ayden I. Scheim PhD Tara Lyons PhD Chavisa Horemans MES BFA Mona Loutfy MD FRCPC MPH 《Health & social care in the community》2021,29(5):e33-e46
Transgender (trans) women experience barriers to access to HIV care, which result in their lower engagement in HIV prevention, treatment and support relative to cisgender people living with HIV. Studies of trans women's barriers to HIV care have predominantly focused on perspectives of trans women, while barriers are most often described at provider, organisation and/or systems levels. Comparing perspectives of trans women and service providers may promote a shared vision for achieving health equity. Thus, this qualitative study utilised focus groups and semi-structured interviews conducted 2018–2019 to understand barriers and facilitators to HIV care from the perspectives of trans women (n = 26) and service providers (n = 10). Barriers endorsed by both groups included: (a) anticipated and enacted stigma and discrimination in the provision of direct care, (b) lack of provider knowledge of HIV care needs for trans women, (c) absence of trans-specific services/organisations and (d) cisnormativity in sexual healthcare. Facilitators included: (a) provision of trans-positive trauma-informed care, (b) autonomy and choice for trans women in selecting sexual health services and (c) models for trans-affirming systems change. Each theme had significant overlap, yet nuanced perspective, between trans women and service providers. Specific recommendations to improve HIV care access for trans women are discussed. These recommendations can be used by administrators and service providers alike to work collaboratively with trans women to reduce barriers and facilitators to HIV care and ultimately to achieve health equity for trans women. 相似文献
110.
Todd JS 《Health systems review》1993,26(4):13-4, 16-8